Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Antibodies not only play a major role in clinical diagnostics and biopharmaceutical analysis but also are a class of drugs that are regularly used to treat numerous diseases. The identification of antibody-epitope binding sites is then of great interest to many emerging medical and bioanalytical applications, particularly to design monoclonal antibodies (mAb) mimics taking advantage of amino acid residues involved in the binding. Among relevant antibodies, the monoclonal antibody rituximab has received significant attention as it is exploited to treat several cancers including non-Hodgkin's lymphoma and chronic lymphocytic leukemia, as well as some autoimmune disorders such as rheumatoid arthritis. The binding of rituximab to the targeted cells occurs the recognition of the CD20 epitope. A crystallographic study has shown that the binding area, named paratope, is located at the surface of rituximab. Combining the SPOT method and the complementary surface plasmon resonance technique allowed us to detect an extended recognition domain buried in the pocket of the rituximab Fab formed by four β-sheets. More generally, the present study offers a comprehensive approach to identify antibody-epitope binding sites.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1021/acs.analchem.1c00960 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Phenotypic Changes in a Monocyte Cluster with High Interleukin-1 Beta Expression during Long-Term Anti-CD20 Therapy.
Ann Neurol
August 2025
Department of Molecular Medicine, University of Southern Denmark, Odense, Denmark.
Objective: We aimed to investigate disease-related and anti-CD20 therapy-related changes in peripheral blood mononuclear cells (PBMCs) from multiple sclerosis (MS) patients compared to healthy controls (HC) using multi-omics single-cell analysis.
Methods: Targeted single-cell sequencing of transcriptomes and epitopes was performed on PBMCs isolated from 64 blood samples collected from MS patients at baseline and at 3 time points following anti-CD20 treatment, alongside HC. Multicolor spectral flow cytometry was performed on 15 of the samples.
Predictors of patients with advanced pancreatic cancer undergoing conversion surgery via chemoimmunotherapy with a multifunctional Wilms' tumor 1 (WT1) peptide cocktail-pulsed dendritic cell vaccine.
J Immunother Cancer
July 2025
Department of Cancer Immunology, The University of Osaka Graduate School of Medicine, Suita, Osaka, Japan.
Background: A chemoimmunotherapy regimen consisting of a novel Wilms' tumor 1 (WT1) peptide-pulsed dendritic cell (WT1-DC) vaccine and multiagent chemotherapy was observed to modulate the tumor microenvironment (TME) to an immunostimulatory state, resulting in conversion surgery in seven out of nine patients with unresectable pancreatic ductal adenocarcinoma (UR-PDAC).
Methods: Understanding WT1-specific immunity and the tumor mutational burden is important for predicting the efficacy of WT1-targeted chemoimmunotherapy. Therefore, the memory CD8+T cell subpopulations in WT1-specific cytotoxic T lymphocytes (WT1-CTLs), titers of antibodies against the WT1 epitopes, infiltration of CD103+tissue-resident memory T cells and CD20+cells in the pancreatic TME, gene mutations in plasma circulating tumor DNA (ctDNA) obtained via liquid biopsy, and PDAC cell characteristics were evaluated.
Design of a water-soluble CD20 antigen with computational epitope scaffolding.
Protein Sci
August 2025
Department of Biochemistry and Biophysics, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.
The poor solubility of integral membrane proteins in water frequently hinders studies with these proteins, presenting challenges for structure determination and binding screens. For instance, the transmembrane protein CD20, which is an important target for treating B-cell malignancies, is not soluble in water and cannot be easily screened against potential protein binders with techniques like phage display or yeast display. Here, we use de novo protein design to create a water-soluble mimic of the core epitope of the CD20 dimer ("soluble CD20").
View Article and Find Full Text PDFResemblance-Ranking Peptide Library as a Representation of a Complex Proteome.
Methods Mol Biol
July 2025
Institute of Microstructure Technology, Karlsruhe Institute of Technology (KIT), Eggenstein-Leopoldshafen, Germany.
Peptide arrays facilitate the exploration of protein-protein interactions, allowing for analysis at the amino acid level. This study introduces a "deep screening" technique to represent entire proteomes with peptides, thereby revealing novel interactions that are not detectable with protein-only methods. We developed a method to construct a peptide library based on genomic peptide similarity, prioritizing peptides with the highest occurrence in the proteome.
View Article and Find Full Text PDFCharacterization of anti-canine CD20 antibody 4E1-7-B_f and comparison with commercially available anti-human CD20 antibodies.
PLoS One
June 2025
Laboratory of Molecular Diagnostics and Therapeutics, Joint Graduate School of Veterinary Medicine, Yamaguchi University, Yamaguchi, Japan.
This study characterizes the previously reported anti-canine CD20 antibody 4E1-7-B_f and compares this with commercially available anti-human CD20 antibodies, rituximab and an obinutuzumab biosimilar. While the obinutuzumab biosimilar exhibited binding to canine CD20 in a CD20-transduced cell line, canine B-cell lymphoma cell line (CLBL-1/luc), and canine CD21 + B cells from healthy dogs, functional assays revealed the superiority of 4E1-7-B_f in antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity activities over those of the obinutuzumab biosimilar. Epitope analysis suggested an extracellular region on canine CD20 targeted by 4E1-7-B_f.
View Article and Find Full Text PDF